Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer

Singapore Medical Journal

Volumn 39, Issue 8, 1998, Pages 357-358

  Soh, L T ^a   Tan, E H ^a   Ang, P T ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

Chemotherapy; Lung cancer; MIC; Non small cell; Palliative

Indexed keywords

CISPLATIN; IFOSFAMIDE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCINS; NEOPLASM STAGING; PALLIATIVE CARE; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0031660484     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Grilli BR, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993; 11:1866-72.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
3. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer a meta-analysis. Lancet 1993; 342:19-21.
4. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: Treatment good enough to compare. Br J Cancer 1988; 58:359-61.
5. Rosell R, Maestre J, Font A, et al. A randomized trial of mitomycin/ifosfamiade cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small lung cancer. Semin in Oncol 1994; 21 (Suppl 4):28-33.
6. Osken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
7. Rigas JR, Kris MG. New chemotherapeutic agents. In: Roth JA, Cox JD, Hong WK, eds. Lung cancer. Oxford: Blackwell, 1993:252-69.
8. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomised trial investigating two dosage schedules. Ann Intern Med 1981; 95:414-20.
9. Klastersky J. VP 16 and cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1985; 12:17-20.
10. Bunn PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16 (suppl 6):10-21.
11. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Group study. J Clin Oncol 1986; 4:702.
12. Woods RL, Williams CJ, Levi J, et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61:608-11.